Genmab A/S Files 6-K Report
Ticker: GNMSF · Form: 6-K · Filed: Apr 15, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Apr 15, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-k, registration-statement
Related Tickers: GMAB
TL;DR
Genmab filed a 6-K, mostly procedural. No new financials here.
AI Summary
Genmab A/S filed a Form 6-K on April 15, 2024, to be incorporated by reference into its existing S-8 registration statements. This filing does not contain new financial data but serves as an update for its SEC filings.
Why It Matters
This filing is primarily procedural, ensuring Genmab A/S's registration statements remain current with the SEC. Investors should look for other filings for operational or financial updates.
Risk Assessment
Risk Level: low — This is a routine SEC filing and does not contain new material information that would typically impact risk.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 0001558370-24-005097 (filing_id) — Accession Number
- 20240415 (date) — Filing Date
- Form S-8 (filing_type) — Incorporated by reference into registration statements
FAQ
What is the purpose of this Form 6-K filing by Genmab A/S?
The purpose of this Form 6-K is to be incorporated by reference into Genmab A/S's existing registration statements on Form S-8 (File Nos. 333-232693, 333-253519, 333-262970 and 333-277273).
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on April 15, 2024.
Does this filing contain new financial information for Genmab A/S?
This filing does not appear to contain new financial information; it is primarily for incorporation by reference into existing registration statements.
What is the principal executive office address for Genmab A/S?
The principal executive offices are located at Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Under which SEC Act is this report filed?
This report is filed under the Securities Exchange Act of 1934.
Filing Stats: 233 words · 1 min read · ~1 pages · Grade level 13.9 · Accepted 2024-04-15 13:17:23
Filing Documents
- tmb-20240415x6k.htm (6-K) — 19KB
- tmb-20240415xex99d1.htm (EX-99.1) — 66KB
- tmb-20240415xex99d1a.htm (EX-99.1(A)) — 5809KB
- tmb-20240415xex99d1001.jpg (GRAPHIC) — 5KB
- tmb-20240415xex99d1a001.jpg (GRAPHIC) — 5KB
- 0001558370-24-005097.txt ( ) — 5908KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970 and 333-277273 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. nthony GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: APRIL 15, 2024 EXHIBIT INDEX O Exhibit Description of Exhibit 99.1 Company Announcement Dated April 15, 2024: Transactions in Connection with Share Buy-back Program 99.1(a) Appendix: Share Buy-Back Program Transactions April 8 to 12, 2024